Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

tgAAC 94

Drug Profile

tgAAC 94

Alternative Names: rAAV2-TNFR:Fc; tgAAC11; tgAAC94; tgAAV-TNFR:Fc; TNFR:Fc gene therapy

Latest Information Update: 14 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Targeted Genetics
  • Developer Armata Pharmaceuticals
  • Class Antirheumatics; Gene therapies
  • Mechanism of Action Gene transference; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Suspended Periodontal disorders; Rheumatoid arthritis

Most Recent Events

  • 09 May 2019 C3J Therapeutics has merged with AmpliPhi Biosciences Corporation to form Armata Pharmaceuticals
  • 08 Apr 2011 Genzyme Corporation has been acquired by sanofi-aventis
  • 09 Mar 2011 Targeted Genetics Corporation is now called AmpliPhi Biosciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top